1. 1 Hasserjian RP, Orazi A, Brunning RD, et al. Myelodysplastic syndromes: Overview. In : Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed, Lyon, IARC. 2017; pp. 98-106.
2. 2 Hasserjian RP, Head DR. Myelodysplastic syndromes. In : Jaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Martinez L (eds). Hematopathology. 2nd ed, Philadelphia, Elsevier. 2017; pp. 793-816.
3. 3 Arber DA, Orazi A, Hasserjian RP, et al. Introduction and over view of the classification of myeloid neoplasms. In : Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed, Lyon, IARC. 2017; pp. 16-27.
4. 4 Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology. 2007; 74: 97-114.
5. 5 Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018; 93: 129-147.